Interview 26 Apr 2017 Infographic: Who’s who in the mRNA Therapeutics Field in Europe? The young field of mRNA therapeutics is booming and generating huge expectations. Which are the main players in Europe turning them into a reality? Therapies based on mRNA promise better vaccines and therapeutics by instructing the body to produce its own just by reading the instructions written in the RNA sequence. Thought for a long time to […] April 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2017 Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […] April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 24 Apr 2017 ‘Meat’ the Founder behind the Lab-Grown Burger Investors are Queuing for Mark Post is a researcher at the University of Maastricht and co-founder and CSO of Mosa Meat, the Dutch company that will bring the first lab-grown beef burger to the market. I asked him about his motivations and plans to make cultured meat a reality in the coming decade. Cultured meat is an animal-free, lab-grown […] April 24, 2017 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Apr 2017 Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance Anna Dumitriu’s latest bioart piece is a historic dress carrying bacteria genetically modified using CRISPR and opens the debate on antibiotic resistance. A wartime women’s suit is the canvas where Anna Dumitriu paints the history of antibiotics. The holes and stains in the suit are patched and embroidered with silk that has been dyed with E. […] April 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 20 Apr 2017 Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years Philip talked to Stefan Weber, CEO of Newron Pharmaceuticals, in our first meetup in Munich last week. His company has launched a new drug that could offer many more benefits than current medications to patients with Parkinson’s. Stefan discussed how failure can be an important part of success and what being European means in biotech. […] April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2017 New French Biotech Seed Fund Raises €65M in its First Closing Advent France Biotechnology has launched its first seed fund for Life Sciences with the support of Bpifrance and Advent Life Sciences. Advent France Biotechnology, founded in 2015, has exceeded its initial fundraising target at the first closing. Its Seed-Fund I now counts with €64.75M that will be invested predominantly in France. The funds will back entrepreneurs […] April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 20 Apr 2017 Which EU Immuno-Oncology Company are you Cheering for? Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one do you think is doing it best? The field of immuno-oncology is overcrowded, and there’s plenty of companies pushing to make their cutting-edge technology a […] April 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2017 Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials in which the placebo beat its allergy immunotherapy. Circassia Pharmaceuticals has released the results from a Phase IIb trial for a house dust mite allergy immunotherapy. Although the treatment greatly reduced allergy symptoms in the patients, so did the placebo, making […] April 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Next-Gen Cancer Antibody Technology from Germany enters the Clinic Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has initiated a Phase I trial testing its next-generation immuno-oncology technology in patients suffering from solid tumors, non-Hodgkin’s lymphoma (NHL) and acute myeloid leukemia (AML). The candidate […] April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 French Oncolytic Virus Vaccine for Breast Cancer enters Phase II After positive results in Phase I, Transgene has started Phase II with Pexa-Vec in combination with chemotherapy to treat breast cancer and sarcoma. After years of financial instability, Transgene is stepping up its game in cancer immunotherapies. Last year, its first Phase III trial and a deal with Merck and Pfizer brought the hopes of investors […] April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2017 France Approves Trials for the First Eye Gene Therapy Free of Viral DNA Eyevensys has received regulatory approval in France to start clinical trials using eye gene therapy technology that eliminates the need for viral vectors. The French biotech Eyevensys has been cleared by the French Product Security Regulatory Agency (ANSM) to proceed into the clinic with its EyeCET platform. The company is developing this gene therapy platform […] April 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2017 New Grant to Advance a Whole New Treatment Against Parkinson’s in the UK Mission Therapeutics has received a grant to support the development of a novel approach to treating Parkinson’s that is attracting top partners worldwide. Right on time for World Parkinson’s Day today, Mission Therapeutics has announced it has been awarded a research grant from the Michael J. Fox Foundation in the US. Named after its founder, the star of […] April 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email